Drug intelligence / Profile preview

BAT8001

Development stage: Phase 3
Lead developer: Bio-Thera Solutions
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BAT8001 is an antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor-2 (HER2). It is composed of a trastuzumab biosimilar linked to the drug-linker Batansine, a maytansine derivative. BAT8001 is developed by Bio-Thera Solutions for treating HER2-positive cancers, particularly breast cancer. Its mechanism of action involves inducing apoptosis and inhibiting mitosis by targeting HER2-expressing cells.

Other names: Anti-ErbB2 antibody drug conjugateAnti-ErbB-2 antibody drug conjugateAnti-ErbB 2 antibody drug conjugateAnti-HER2 antibody drug conjugateAnti-HER-2 antibody drug conjugateAnti-HER 2 antibody drug conjugate

Targets

TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on BAT8001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAT8001.

Explore the full profile